🔗 Share this article

While America continues making historic changes to its vaccine schedules, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by questioning Covid vaccinations throughout the global health crisis and has zeroed in on possible fatalities after COVID-19 vaccination in her brief tenure at the FDA.

Proposed Changes to Pediatric Vaccine Program

Public health authorities planned to announce sweeping changes to the childhood vaccine schedule in December, bringing the US with the Danish vaccine program, it is understood – a significant shift that would put the US out of alignment with much of the international standard with little proof for improved outcomes. This reveal has been pushed back until the new year.

Rather than the director of the vaccine center, Høeg is scheduled to speak at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to lead the office this calendar year.

A New Direction at the FDA

Høeg's temporary position may indicate a closer partnership between the drug and biologics branches as Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Høeg has repeatedly called for halting specific childhood vaccine recommendations in the US to become more like the Danish model, a country with universal health coverage and a population about the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccination policy – traditionally the purview of Dr. Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Qualifications

Høeg has little discernible track record in pharmaceutical research, regulation or management, which has been typical for previous leaders of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a major agency. She lacks background in drug approvals.”

Past commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who ran the center have had.”

CDER has an enormous workload at the agency, Woodcock emphasized.

“Everybody just focuses on the novel medication approvals, but the generic drug division authorizes numerous generic drugs. There is also a biosimilars program, over-the-counter program and more, and each of these have to be managed,” Dr. Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

Additionally, a substantial management element to the position, which oversees over 5,000 personnel. “It’s a huge management job, if you perform it correctly,” Woodcock added.

Agency Reaction and Controversial Policies

Regarding questions about Høeg’s credentials and whether this appointment indicates increased cooperation among agency officials on immunizations, a representative stated that the “concerns are based on incorrect assumptions”.

“This background matches the duties of her position,” the spokesperson explained, noting the time Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's controversial expedited review system, a contentious rapid drug-approval program that allegedly concerned her preceding directors. “By what process are these drugs being selected for this expedited pathway? Who takes the choices?” Howard asked. “There’s a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he stated, “the agency looks to be trending towards laxer regulations of pharmaceuticals, with the exception of vaccines.”

Documented Track Record on Immunizations

With immunizations, Høeg has a more documented, if problematic, history, some experts said. She authored a analysis using unconfirmed crowd-sourced reports to determine the rate of myocarditis following COVID-19 immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the new administration included revising guidelines for recently developed shots and halting “optional” immunizations, she said following the vote on a audio program. At the agency, Dr. Høeg has according to sources floated the idea of preventing young men from obtaining COVID-19 vaccinations.

“She’s an all-around ideologue who starts off with her beliefs and reverse-engineers to fit the evidence in a highly disingenuous, untruthful way,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined other skeptics, {like|